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The proximal promoter of the kallikrein-related peptidase 3 gene
(KLK3/PSA) contains a single-nucleotide polymorphism (G-158A)
located within the second canonical half-site for the prostate-
specific antigen (PSA) androgen response element 1 (AREI). Pre-
vious studies suggest that this polymorphism may be associated
with higher PSA levels and increase prostate cancer risk. We have
investigated the potential functional significance of this polymor-
phism and its association with prostate cancer susceptibility by
genotyping the G-158A polymorphism in 209 men diagnosed with
prostate cancer and 223 healthy control men in an Australian
Caucasian population. Functional analyses of PSA AREI demon-
strated that the A allele increased binding of AREI to the andro-
gen receptor, as well as increasing transcriptional response to
androgens. Association studies of the G-158A polymorphism
demonstrated that men with an A/A genotype had a 3-fold in-
creased risk for developing prostate cancer [95% confidence in-
tervals (CIs) 5 1.36–6.52] and men with an A/G genotype had a
2.4-fold increased risk (95% CIs 5 1.23–4.81). Under a dominant
model, the A allele conferred a 2.6-fold increased risk for prostate
cancer (95%CIs5 1.37–4.96, P5 0.004). Taken together with the
finding that the G-158A polymorphism is associated with an in-
creased risk of prostate cancer in Australian men, our functional
data suggest that the presence of the A allele in AREI may, in part,
account for the altered PSA regulation seen in prostate cancer.
Introduction
Prostate-specific antigen (PSA, kallikrein-related peptidase 3) is a ser-
ine protease that is part of the kallikrein superfamily (1,2), produced
predominantly by the prostate and primarily by secretory luminal
epithelial cells therein (3). Serum PSA is the most commonly used
clinical biomarker for prostate cancer. In the prostate, PSA is regu-
lated by androgens and the cellular effects of androgens are mediated
by the androgen receptor (AR). Upon androgen binding to the AR,
a sequence of cellular events occurs that ultimately results in the
translocation of the AR into the nucleus, where it binds to androgen
response elements (AREs) in the promoters of target genes to initiate
transcription. These AREs consist of palindromic hexameric repeats
separated by a three-nucleotide spacer (GGTACAnnnTGTTCT) (4).
Three AREs have been described in the promoter of the PSA gene,
two are found within the proximal promoter at 170 (AREI) and
394 (AREII) and the third ARE is located in the distal enhancer
region at 4200 (AREIII) (5–7).
Cramer et al. (8) have shown that a number of polymorphisms in
the PSA gene are associated with changes in serum PSA levels and
a recent editorial has emphasized the importance of these polymor-
phisms as predictive biomarkers (9). The PSA AREI harbours a poly-
morphism (rs266882) that results in a substitution of a guanine by an
adenine 158 bases upstream of the transcription start site (G-158A)
(10). This polymorphism is located in the second canonical half-site
of AREI, and potentially affects transcriptional control of AR-regu-
lated expression. Indeed, this single-nucleotide polymorphism (SNP)
has been associated with increased serum PSA levels (11–14). It was
recently reported that there was no difference in transcriptional activ-
ity between the two AREI alleles in response to androgens in both
LNCaP and PC-3 cells co-transfected with wild-type AR (15); how-
ever, it is possible that subtle differential interactions between the two
AREI alleles and the AR were not measurable in that study (15).
Given the potential importance of the PSA G-158A SNP, a number
of studies have investigated the association between this SNP and
prostate cancer susceptibility in different populations. An initial as-
sociation study found a 3-fold increased risk for developing prostate
cancer in men with the GG genotype and, furthermore, this risk was
compounded to 5-fold when associated with short AR alleles (16).
However, subsequent studies have been conflicting, showing an asso-
ciation between increased risk of prostate cancer with either the A
(14,17,18) or G (19,20) allele, whereas others have found no signif-
icant association with either allele (21–23). The G-158A SNP has also
been reported to be associated with prostate tumour volume, stage/
grade of disease and circulating tumour cells (11–14,16,20).
Given the importance of the AR-signalling axis in prostate cancer
aetiology, and the observation that serum PSA is frequently elevated
in men with prostate cancer, we used a number of in vitro assays to
elucidate the functional significance of this polymorphism. We also
conducted a case–control study in an Australian Caucasian popula-
tion, in order to determine the association between the PSA G-158A
SNP and risk of prostate cancer in this population.
Materials and methods
Tissue culture and reagents
LNCaP and 22Rv1 prostate cancer cell lines were obtained from American
Type Tissue Culture Collection (Manassas, VA). All cells were initially main-
tained in RPMI 1640 supplemented with 10% fetal calf serum (Invitrogen,
Carlsbad, CA) and 50 U/ml penicillin G and 50 lg/ml streptomycin (Roche,
Basel, Switzerland), and grown in a 37C incubator in 5% CO2. At 70%
confluency, cells were serum-starved for 48 h in 2% charcoal-stripped fetal calf
serum (Hyclone, South Logan, UT), prior to the addition of androgens for
androgen regulation experiments.
Purification of AR–DNA-binding domain
A fragment encoding 117 amino acids of the AR–DNA-binding domain (DBD)
and the ligand-binding domain was amplified from T-47D breast cancer cDNA
Abbreviations: AR, androgen receptor; ARE, androgen response element;
BPH, benign prostatic hyperplasia; CI, confidence interval; DBD, DNA-binding
domain; DHT, dihydrotestosterone; EMSA, electrophoretic mobility shift as-
say; OR, odds ratio; SNP, single-nucleotide polymorphism; PCR, polymerase
chain reaction; PSA, prostate-specific antigen; TNM, tumor, node, metastasis.
yThese authors contribute equally to this work.
 The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version
of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are
attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
by standard polymerase chain reaction (PCR) using primers ARDBD-F (5#-
ctctctggatccgccagggaccatgttttg-3#) and ARDBD-R (5#-ctactagaattccttctgggttgtc-
tcctc-3#). Primers were designed with BamHI and EcoRI restriction sequence
overhangs to facilitate subcloning into the pGEX-2T multiple-cloning site
(Amersham Biosciences, Uppsala, Sweden) prior to transformation into
Escherichia coli JM109 cells (Stratagene, La Jolla, CA). Fusion protein,
AR-DBD/glutathione S-transferase, expression was induced by the addition of
1 mM isopropyl-b-D-thiogalactoside (Promega, Madison, WI) and the fusion
protein was purified by batch chromatography on glutathione-sepharose 4B
(Amersham, Piscataway, NJ). Purification and protein size was assessed by
sodium dodecylsulphate–polyacrylamide gel electrophoresis and quantified by
Coomassie Brilliant Blue protein staining (Bio-Rad, Hercules, CA).
Electrophoretic mobility shift assay
Oligonucleotide sequences used in electrophoretic mobility shift assay (EMSA)
and limited proteolysis assays were designated PSA-AREI-G (sense: 5#-tcgactt-
gcAGAACAgcaAGTGCTagctg-3# and anti-sense: 5#-agctcagctAGCACT-
tgcTGTTCTgcaag-3#; where the ARE is underlined, base changes are
indicated in bold and the hexameric half-sites are represented by capital letters)
or PSA-AREI-A (sense: 5#-tcgacttgcAGAACAgcaAGTACTagctg-3# and anti-
sense: 5#-agctcagctAGTACTtgcTGTTCTgcaag-3#). DNA oligonucleotides
were labelled using the biotin 3# end DNA labelling kit (Pierce Biotechnology,
Rockford, IL) and annealed to their complementary strand. EMSA was carried
out using the LightShift Chemiluminescent EMSA Kit (Pierce Biotechnol-
ogy) according to the manufacturer’s instructions. Bands were visualized
and quantitated using the Bio-Rad GS-690 imaging densitometre and the
Bio-Rad Multi-Analyst software (Version 1.1, Bio-Rad). Binding experi-
ments with glutathione S-transferase and PSA-AREIA were carried out to
ensure that the AR–DBD and not the glutathione S-transferase moiety was
complexing with the PSA AREs (data not shown). Experiments were con-
ducted in triplicate and data are represented as the mean ± SE from three
independent experiments. The Kd values were determined using allosteric Hill
kinetics and the corresponding binding curves were determined by the Sigma-
Plot statistical software (Version 9.0, Systat Software).
Limited proteolysis assay
EMSA was carried out as above, with the addition of 10 lM CaCl2 to stabilize
trypsin digestion, and performed on 5 lg of nuclear extract from LNCaP and
22Rv1 cells treated with 10 nM R1881 for 12 h. Following 20 min incubation
for DNA–protein complex formation, 0, 10, 20 and 40 ng of trypsin
(Worthington Biochemical Corporation, Templestowe, Australia) was added
for an additional 1 h at room temperature. Samples were then electrophoresed
on 8% non-denaturing acrylamide gels, followed by DNA transfer and visual-
ization as described above.
Luciferase promoter constructs and reporter assays
PSA luciferase promoter constructs for the G and A alleles were generated
using oligonucleotides (PSA AREIX3-G sense: 5#-cttgcAGAACAgcaAGTGC-
TagctctctaattgcAGAACAgcaAGTGCTagctctctaattgcAGAACAgcaAGTGCT-
agcta-3# and anti-sense: 5#-gatctagctAGCACTtgcTGTTCTgcaattagagagct-
AGCACTtgcTGTTCTgcaattagagagctAGCACTtgcTGTTCTgcaaggtacc-3# and
PSA AREIX3-A sense: 5#-cttgcAGAACAgcaAGTACTagctctctaattgcAGAA-
CAgcaAGTACTagctctctaattgcAGAACAgcaAGTACTagcta-3# and anti-sense:
5#-gatctagctAGTACTtgcTGTTCTgcaattagagagctAGTACTtgcTGTTCTgcaat-
tagagagctAGTACTtgcTGTTCTgcaaggtacc-3#; where the ARE is underlined,
base changes are indicated in bold and the hexameric half-sites are represented
by capital letters) consisting of three tandem copies of PSA AREI and its native
flanking sequences (Proligo, Lismore, Australia), and designated PSA-AREIX3-G-
Luc and PSA-AREIX3-A-Luc, respectively. The inserts were designed with
BglII and KpnI restriction site overhangs to facilitate orientation-specific
ligation into the multiple-cloning site of the luciferase pGL3 promoter
vector (Promega). A full-length PSA promoter construct (PSA-5.8-A-Luc)
was generated using primers targeting 5.8 kb of the PSA promoter (PSA 5.8-
A-F: 5#-cacctcgagttcttttcccggtgacatcg-3# and PSA 5.8-A-R: 5#-tcacggacagggt-
gaggaag-3#), amplified from LNCaP DNA. The PCR amplicon was cloned into
pGEM-T and digested with HindIII and XhoI prior to ligation into the
promoter-less pGL3-basic vector (Promega). All promoter constructs were
verified by restriction mapping and direct sequencing.
Luciferase reporter assays were carried out in both LNCaP and 22RvI cells.
Cells were seeded in 24-well plates at a density of 1  105 cells per well and
culture medium was changed to phenol red-free RPMI 1640 and 2% charcoal-
stripped fetal calf serum for 48 h prior to transfection. Transient transfection
was carried out with PSA-AREIX3-G-Luc, PSA-AREIX3-A-Luc, pGL3 pro-
moter or PSA-5.8-A-Luc with Opti-MEM-I reduced serum medium (Invi-
trogen), and 2 ll of lipofectamine 2000 (Invitrogen) per well. Cells were
co-transfected with the Renilla luciferase construct (phRL-TK, Promega) to
serve as a transfection efficiency control. Luminescence was measured by the
Dual-Luciferase Reporter Assay System (Promega). Androgen responsiveness
of the constructs was assessed by treating transfected cells with either 10 nM of
dihydrotestosterone (DHT) or 10 nM of the synthetic androgen R1881. Statis-
tical significance was assessed using the Student’s t-test from three indepen-
dent data sets that were each carried out in quadruplicate.
Molecular dynamic simulation/modelling
All molecular modelling manipulations were carried out within the YASARA
Dynamics Program (Version 6.2.4) (24). The starting point was the previously
published structure of the AR–DBD, binding to a canonical ARE PDBid 1R4I
(25). The sequence of the canonical ARE was mutated in silico, so that it
accorded with either the 158A or G sequences. All water molecules resolved
in the starting structure were removed, hydrogens were added where missing
and the following missing lysines were reconstructed: A protomer Lys 573 and
575 and B protomer 540, 573, 575 and 588. Molecular dynamic simulation was
carried out with a cut-off of 7.6 A˚ to delimit non-bonding interactions, and
a particle Ewald mesh approximation was used for longer range electrostatic
forces. Simulations were carried out in a cell with periodic boundaries that
extended 10 A˚ beyond the target structure in all three axes. This was filled with
water molecules, which were then subject to simulated annealing energy min-
imization. Counter ions (six sodium ions) were then added to neutralize the
ensemble, pKa values for all side chains were calculated and protons placed
according to ionization status. Following neutralization, resulting conforma-
tional stress in the protein was released by energy minimization. Simulations
were then conducted at 298 K, at constant pressure, with molecular snapshots
being taken every 10 ps for a total of 500 ps. Snapshots for every 50 ps were
then overlaid and differences in hydrogen bonding and residues displacements
between the 158A and 158G structures were tabulated and identified. Cal-
culation of root mean square deviations between the starting structure and the
simulated complex showed good concordance. Average root mean square de-
viation for all atoms of the structure was 1.13 A˚ (structure not shown), in-
dicating that the simulation procedure did not significantly change the
arrangement of the naturally folded protein structure.
Patient samples
Men recently diagnosed with prostate cancer (n 5 209) and healthy male
blood donor controls (n 5 223) participated in the association study. Prostate
cancer was defined as clinically diagnosed, and pathologically confirmed,
cancer of the prostate, following presentation with an abnormal serum PSA
and/or lower urinary tract symptoms. The healthy controls had no personal
history of any cancer. Men with prostate cancer were recruited within 2 years
of diagnosis, through physician referrals from Brisbane Private Hospital
(n 5 191), Royal Brisbane Hospital (n 5 4) and Princess Alexandra Hospital
(n5 14) in Brisbane, Queensland. Healthy male blood donors were recruited
through the Australian Red Cross Blood Services in Brisbane, Queensland.
All participants were unrelated Caucasian men between 18 and 91 years
of age, and all subjects gave written informed consent and were interviewed
by one of the investigators. Comprehensive epidemiological questionnaires
and 8 ml of blood were obtained for each participant and, in addition,
detailed clinical data (including serum PSA levels at diagnosis, tumor, node,
metastasis (TNM) staging and Gleason score) were obtained for cases. All
samples and data from the controls were deidentified. The study protocol was
approved by the Human Research Ethics Committees of Queensland Univer-
sity of Technology, Queensland Institute of Medical Research, the Mater
Hospital (for Brisbane Private Hospital) and the Royal Brisbane and Princess
Alexandra Hospitals, Queensland.
DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood leukocytes using the
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions, or using the salt extraction method described by
Miller et al. (26).
Genotypic analysis of the PSA G-158A SNP was carried out using PCR–
restriction fragment length polymorphism analysis as described previously
(27). Briefly, 25 ll reactions containing 50 ng genomic DNA, 20 pmol of each
primer (PSA-F and PSA-R), 1 PCR buffer, 0.75 mM MgCl2, 200 mM dNTP
and1 U Taq polymerase (Platinum Taq, Invitrogen) were cycled at 95C for
2 min, followed by 28 cycles of 94C for 30 s, 59–64C for 30 s, 72C for 30 s
and a final cycle of 72C for 8 min. Amplicons were digested at 37C for 4–8 h
with 10 U restriction endonuclease NheI (New England Biolabs, Beverley,
MA) and electrophoresed on 2.5% ethidium bromide-stained agarose gels.
Genotypes were verified by repeating PCR–restriction fragment length poly-
morphism on 20 random samples.
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Statistical analysis
Genotype and allele frequencies for the PSA G-158A polymorphism were
calculated for the patient and healthy control groups. Comparisons of allele
and genotype distribution and their association with prostate cancer suscepti-
bility, socio-demographics and clinical data were performed under co-
dominant and dominant models, using chi-square test and multivariate logistic
regression analysis, in SPSS for Windows (Release 13.0, 2004. Chicago:
SPSS) Hardy–Weinberg equilibrium analysis for each group was evaluated
using Ottutil Utility Program for Analysis of Genetic Linkage (J. Ott, 1998).
Results
The PSA AREI alleles bind with different affinity to the AR
EMSA experiments were carried out to assess whether there was any
difference in AR-binding affinity between the two PSA AREI alleles,
using a fragment comprising 117 amino acids of the AR–DBD and
ligand-binding domain (Figure 1A). Incubation of PSA-AREI-G and
PSA-AREI-A with 0.03–1.5 lg of AR–DBD resulted in the formation
of a distinct high-molecular weight shift for both alleles (Figure 1B),
and PSA-AREI-A bound with greater affinity compared with PSA-
AREI-G across all concentrations of AR–DBD. The Kd binding curves
for PSA-AREI-G and PSA-AREI-A are presented in Figure 1C and
show a 2-fold difference in binding affinities between the alleles (0.6 ±
0.15 lM and 0.3 ± 0.05 lM, respectively).
The PSA AREI alleles mediate differential binding of endogenous
nuclear receptor complexes and are cell specific
Limited proteolysis assays were carried out to assess whether the PSA
AREI alleles mediated differential co-activator complex stability and/
or altered endogenous AR conformation in vitro. When incubated
with nuclear extracts from both LNCaP and 22Rv1 cells treated with
R1881, both AREI alleles showed multiple shifts, with only two shifts
in common (Figure 2). Differences in shift intensities between the
alleles for numerous protein–AREI complexes suggest that these al-
leles bind with different affinity to the receptor complexes. Further-
more, proteolytic protection of protein–AREI complexes for the A
allele was observed in samples that were treated with trypsin and
indicates marked differences in proteolytic sensitivity between
protein–AREI-G/A complexes in both LNCaP and 22Rv1 cells.
The PSA AREI A allele is more transcriptionally responsive to
androgens
Reporter assays were carried out with constructs containing three
tandem copies of either PSA AREI allele (PSA-ARE1X3-G-Luc or
PSA-ARE1X3-A-Luc) (Figure 3A), and androgen-induced transacti-
vation assays were carried out with DHT or R1881 in both LNCaP and
22Rv1 cells, in order to determine whether there were allelic differ-
ences in the induction of AR activity. The full-length promoter con-
struct, PSA-5.8-A-Luc, was androgen responsive in both cell lines
when compared with vehicle control (Figure 3B and C), and there
was ,1-fold difference in pGL3 promoter activity in both DHT- and
R1881-treated LNCaP and 22Rv1 cells, confirming that the vector
backbone was not androgen responsive (Figure 3B and C).
The PSA AREI-A allele was more responsive to both DHT and
R1881 in both LNCaP and 22Rv1 cells, compared with the PSA
AREI-G allele. Although not statistically significant, there was
a 1.35-fold (DHT) and 6-fold (R1881) higher transcriptional response
for PSA-AREIX3-A-Luc compared with PSA-AREIX3-G-Luc in
LNCaP cells (Figure 3B). In 22Rv1 cells, PSA-AREIX3-A-Luc had
a 1.6- and 1.4-fold higher transcriptional activity over PSA-AREIX3-
G-Luc in response to R1881 and DHT, respectively (Figure 3C). The
difference in androgen regulation between PSA-AREIX3-A-Luc and
PSA-AREIX3-G-Luc was statistically significant for the DHT-treated
22Rv1 cells (P 5 0.04).
The G-158A polymorphism introduces two extra hydrogen bonds with
the AR–DBD
A series of in silico simulations of AR–DBD binding to the poly-
morphic ARE were conducted to achieve a structural understanding
of the differences in Kd for the two alleles. The simulation procedure
was conducted with the 158A/G sequences substituted for the ca-
nonical ARE and root mean square deviation calculations on the
resulting complexes showed substantially higher average deviations
of 1.79 A˚ for the A allele and 1.63 A˚ for the G allele compared with
Fig. 1. EMSA analysis for differences in binding affinity conferred by the G-158A SNP with the AR–DBD. (A) Schematic of human AR–DBD used in EMSA and
limited proteolysis experiments. The purified AR–DBD comprises residues of the N-terminal domain (NTD), the two zinc finger motifs (Zinc Finger 1/2) in the
DBD and a region of the ligand-binding domain (LBD) that includes the C-terminal extension (CTE). (B) Band shifts of PSA-AREI-G (lanes G) and PSA-AREI-A
(lanes A) with increasing amounts (0.03–1.5 lg) of AR–DBD. (C) Binding curves plotting the percentage of complexed DNA probe (% retardation) for PSA-
AREI-A (open circles) and PSA-AREI-G (closed circles) with 0.03–1.5 lg of AR–DBD. Data are represented as the mean ± SE from three independent
experiments.
J.Lai et al.
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the starting template structure. The majority of this displacement
occurred in the B protomer (Figure 4A), which contacts the poly-
morphic bases in the ARE. Comparative analysis of protomer B for
both the 158A and 158G complexes showed that maximum dis-
placement occurred at residue ARG568. This displacement corres-
ponds with the formation of two extra hydrogen bonds with base
160G of the oligonucleotide (Figure 4B). Significantly, the equi-
valent residue in the A protomer shows very little displacement when
the two model complexes are compared. The binding energy of the
DNA–protein complex for both the 158A and 158G alleles was
calculated as 40.0 and 36.9 kJ, respectively, which was comparable
with the dissociation constants measured previously by EMSA anal-
ysis. This provided validation of the simulation approach used to
analyse the structural features responsible for differences in binding
between the alleles.
The A allele in PSA AREI is associated with increased prostate cancer
risk in Australian men
In total, 209 men recently diagnosed with prostate cancer and 223
healthy male blood donor controls participated in this study. Table I
illustrates a number of the socio-demographic and clinical character-
istics of the populations studied. Frequencies for the PSA G-158A
polymorphism in the study groups are summarized in Table II and
both cases and controls were in Hardy–Weinberg equilibrium (P 5
0.67 and P 5 0.31, respectively). Under a co-dominant model
(adjusted for age), both the A/G and A/A genotypes were associated
with an increased risk of developing prostate cancer (Table II): men
with the A/G genotype had a 2.4-fold increased risk [95% confidence
intervals (CIs) 5 1.23–4.81] and the A/A genotype was associated
with a 3-fold increased risk (95% CIs 5 1.39–6.52), with significant
evidence for trend (P5 0.012). Under a dominant model (adjusted for
age), the A allele was associated with a 2.6-fold increased risk of
developing prostate cancer (95% CIs5 1.37–4.96, P5 0.004). There
was no allelic or genotypic association between the PSA G-158A
polymorphism and various clinical markers in men with prostate can-
cer, including serum PSA at diagnosis (P5 0.34), TNM staging (P5
0.64) or Gleason score (P 5 0.86). Although all analyses were ad-
justed for age, the age distributions of the cases and controls were
significantly different (P, 0.0001). An additional subgroup analysis,
therefore, was performed to determine whether a better age-matched
control group (i.e. controls aged 50 years and over, n 5 115, median
age5 60 years)gave similar results. In fact, although the crude odds ratios
(ORs) were somewhat higher for the age-restricted group as controls on
both a co-dominant model [ORAG 5 2.41 (95% CIs 5 1.38–4.20) and
ORAA 5 3.26 (95% CIs 5 1.69–6.31)] and a dominant model [crude
ORAA/AG5 2.66 (95% CIs5 1.58–4.50), P, 0.0001], the results of the
age-adjusted analyses were very close to those for the overall group
[ORAG 5 2.42 (95% CIs 5 1.24–4.72); ORAA 5 3.07 (95% CIs 5
1.41–6.68) and ORAA/AG 5 2.62 (95% CIs 5 1.39–4.92), P 5 0.003].
Discussion
Given the importance of PSA and androgens in early prostate (patho)-
physiology, and the suggestion that the G-158A polymorphism in
AREI of the PSA gene might moderate the role of PSA in prostate
cancer and be associated with serum levels, we sought to determine
the functional significance of this polymorphism using a number of
in vitro assays. Further to these findings and following conflicting
Fig. 3. Luciferase reporter assays assessing differences in androgen
responsiveness conferred by the PSAG-158A SNP. (A) Schematic of
constructs used in the analyses. Androgen-regulated promoter assays were
carried out in (B) LNCaP and (C) 22Rv1 cells. Data were normalized to
Renilla luciferase activity and expressed as the mean fold increase over
vehicle control treatments (1% ethanol) ± SE from three independent
experiments. Androgen induction was carried out with both DHT (black
bars) and R1881 (grey bars). The asterisks above the bars indicate
a statistically significant difference in promoter activity between the two
allelic constructs (P 5 0.05).
Fig. 2. Limited proteolysis analysis assessing differential AR conformation
and/or complex stability conferred by the PSA G-158A SNP in LNCaP and
22Rv1 cells. Nuclear fractions were extracted from cells that were treated
with 10 nM R1881 for 12 h. After formation of receptor–DNA complexes by
incubating nuclear extracts (NE) with biotin-labelled PSA AREI-G or PSA
AREI-A, samples were then digested with increasing amounts of trypsin
(0—40 ng) for 1h at room temperature. Arrows indicate shifts that have
different intensity between the two alleles.
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results obtained from previous association studies of the G-158A
polymorphism with prostate cancer risk, we conducted a case–control
study to examine the association between this polymorphism and
prostate cancer risk in Australian men.
In vitro EMSA analysis with purified AR–DBD resulted in a single
shift that is consistent with observations by other groups (5,6) and
demonstrated that the PSA AREI A allele binds with 2-fold greater
affinity to the AR–DBD compared with the PSA AREI G allele. Our
EMSA data are also supported by a previous PCR-based sequence
selection study that showed an 2-fold greater selection for adenines
over guanines at the þ5 position (for which the G-158A SNP is
positioned) (28).
We then carried out limited proteolysis experiments to determine
whether the PSA G-158A SNP has an allosteric effect on the AR that
may result in altered receptor dimerization/conformation and, in turn,
mediate differential cofactor recruitment or affect AREI–receptor
complex stability. Trypsin digestion in the 22Rv1 experiments demon-
strated an increase in the lowest shift intensity, which coincides
with a decrease in intensity for the higher molecular weight shifts
Fig. 4. In silico modelling for structural differences conferred by the G-
158A SNP. (A) Model of AR–DBD protomers binding to158A and158G
oligonucleotides. The dimeric protein components of both complexes have
been superimposed on to a single DNA molecule and are represented by an
alpha carbon trace coloured according to displacement from the starting
template structure (Structure file PDBid 1I4R) with red indicating maximum
displacement and blue minimum displacement. Note that only the B
protomer shows significant displacement from the original structure. DNA is
represented in space-filling mode and coloured grey, and zinc atoms are
coloured green. DNA sequence bound by protomers A and B is also shown
schematically. (B) Molecular dynamic simulation of the AR–DBD in
solution. Molecular dynamics of the 158A and 158G AR–DBD models
was followed over a period of 500 ps taking snapshots every 50 ps. Both sets
of snapshots have been overlaid using the bound oligonucleotide as point of
reference. For the sake of clarity, only G-160 of the bound oligonucleotide is
shown. The 158A model snapshots are coloured cyan and the 158G
model snapshots are coloured magenta. Greatest deviation between the two
sets of structures was observed for ARG568 in protomer B. The inset shows
a magnified view of this side chain highlighting the two extra hydrogen
bonds (yellow dashes) formed between the oligonucleotide G-160 and the
B protomer. Note that no significant deflection is observed for this residue in
protomer A.
Table I. Socio-demographic and clinical characteristics of the study
populations
Characteristicsa Men with prostate
cancer (n 5 209) n (%)
Healthy controls
(n 5 223)b n (%)
Age in years (median, range) 68 (50–91) 50 (18–75)
Marital status
Never married 8 (4) 41 (18)
Married/de facto 179 (86) 151 (68)
Divorced/separated/widowed 18 (9) 20 (9)
Unknown 4 (1) 11 (5)
Family history of prostate cancer
No 153 (73) 207 (93)
Yes 56 (27) 16 (7)
Vasectomy status
No 151 (73) 134 (60)
Yes 58 (27) 89 (40)
Smoking status
Never smoked 94 (45) 121 (54)
Former smokerc ,20 pack years 43 (20.5) 49 (22)
Former smokerc .20 pack years 63 (30) 26 (12)
Current smoker ,20 pack years 1 (0.5) 8 (4)
Current smoker .20 pack years 4 (2) 9 (4)
Unknown 4 (2) 10 (4)
Alcohol consumption
Non-drinker 73 (35) 39 (18)
Drinker 132 (63) 175 (79)
Unknown 4 (2) 9 (3)
Highest education level achieved
No formal education/
primary school
31 (15) 6 (3)
Secondary school 116 (56) 71 (32)
Technical college 22 (16) 55 (25)
University 33 (10) 81 (36)
Unknown 7 (3) 10 (4)
TNM staging
pT1 94 (45) Not applicable
pT2 54 (26) Not applicable
pT3 32 (15) Not applicable
pT4 2 (1) Not applicable
Unknown 27 (13) Not applicable
Serum PSA at diagnosis
,4 ng/ml 26 (12) Not measured
4–10 ng/ml 95 (46) Not measured
.10 ng/ml 71 (34) Not measured
Unknown 17 (8) Not measured
Gleason score (Gleason grade 1 þ Gleason grade 2)
,7 178 (85) Not applicable
7 11 (5) Not applicable
Unknown 20 (10) Not applicable
aStudy characteristics differed significantly between cases and controls
(P , 0.01).
bApproximately half the controls (n 5 115) were aged 50 years and over.
cFormer smokers included participants who reported having ceased smoking
at least 1 year before taking part in this study.
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and suggests that the multiple bands in the limited proteolysis assays
are intermediate AR co-regulatory complexes. Limited proteolysis
experiments with both 22Rv1 and LNCaP nuclear extracts demon-
strated that PSA AREI-A bound with greater affinity to the AR and its
associated co-regulators compared with PSA AREI-G. This is consis-
tent with the EMSA analysis that showed a greater binding affinity of
the A allele to the AR–DBD. Differences in shift intensities between
the two PSA AREI alleles after trypsin digestion for some of the shifts
in the LNCaP experiments suggest that DNA–receptor stability is also
altered through allosteric interactions conferred by the AREI alleles
onto the AR, as demonstrated by the higher tolerance of the A allele
to trypsin digestion. Hence, altered AREI–AR interactions are probably
caused by a combination of differential receptor–AREI-binding affini-
ties and subsequent allosteric effects imparted onto the AR and its
co-regulators that ultimately affect receptor–AREI complex stability.
Indeed, DNA-mediated allosteric changes in the AR have been previ-
ously reported in a limited proteolysis experiment comparing cognate
and non-cognate AREs (29). Also of note is that only two common
receptor–AREI complexes were detected when comparing bands
between the two cell lines. The availability of AR co-regulators might,
in part, account for these differences; however, these cell-specific dif-
ferences do not seem to affect the allosteric effects conferred by the
G-158A SNP, suggesting that the A allele may have a more critical
role in recruiting and stabilizing the AR and its co-regulators to the
PSA promoter.
Since there was evidence of altered binding of the PSA AREI
alleles with the AR and differences in receptor–AREIA/G complex
stability, we undertook androgen-regulated reporter assays to deter-
mine whether these data translated to a transcriptional response,
which is ultimately the end point for AR-targeted genomic effects.
The luciferase data demonstrated that the PSA AREI A allele was
significantly more responsive to both the natural (DHT) and synthetic
(R1881) androgens in both LNCaP and 22Rv1 cells. However, it is
difficult at this stage to determine whether the G-158A polymorphism
has any transcriptional effect in a native context and when acting
synergistically with the other PSA AREs. Indeed, it was recently
reported (15) that variant AREI promoter constructs (which includes
AREs I, II and III) were not differentially responsive to androgens.
Interestingly, in the same study, the authors also found no functional
difference in transcriptional activity for the two AREI alleles using
similar tandem constructs as those used in this study. The discrepancy
from the data observed in this and the previous functional study are
probably caused by several experimental differences between the two
studies. For example, in this study, transcriptional activity was nor-
malized to luminescence from Renilla activity, whereas the Rao et al.
(15) study normalized transcriptional activity to b-galactosidase ex-
pression. In our study, cells were starved of steroids for 54 h (48 h
serum-starved and 6 h transfection time) as opposed to 24 h for the
Rao et al. study (15). Hence, incomplete removal of endogenous
androgens in the latter study may also account for the observed differ-
ences between the two studies. Finally, it is possible that transient
expression of the AR in PC-3 cells may be at saturated levels that
mask any subtle differences between the two AREI alleles in response
to androgens.
Molecular modelling of the PSA AREI alleles with an in silico
representation of the AR–DBD predicted the formation of an extra
two hydrogen bonds with the AREI A allele, which would account for
the increased binding observed in the EMSA experiments. Although
modelling was performed with the DBD in isolation, rather than
with an intact AR, the validity of this model was strengthened by
correlation of binding energies calculated for the in silico represen-
tation with those obtained from EMSA experiments. Modelling also
suggested that this difference derives from two extra two hydrogen
bonds formed between the oligonucleotide and ARG568 of protomer B
in the dimeric DBD. Interestingly, the extra bonds are not formed with
the variant nucleotide at 158A/G, but with a nucleotide further
towards the 5# end of the oligonucleotide (160G), common to both
alleles. This suggests that the sequence of the bound DNA can alter
conformation of the bound AR–DBD, which in turn can cause dis-
placements in the bound DNA discrete from variant bases.
Given our observations of the functional importance of the G-158A
polymorphism in PSA AREI, we were encouraged to look for an
association between this polymorphism and prostate cancer risk in
an Australian Caucasian population. Using a dominant model, we
showed that men with at least one A allele had a 2.6-fold increased
risk of developing prostate cancer (95% CIs 5 1.37–4.96, P 5 0.004)
and, under a co-dominant model, the AA genotype was associated
with a 3-fold increased risk (95% CIs 5 1.36–6.52). Although the
age distributions of the case and control groups were only crudely
matched, this does not explain the basis of the observed association,
as subgroup analyses limited to controls aged 50 years and over
yielded equivalent age-adjusted results.
The role of the G-158A polymorphism in disease susceptibility
has still to be elucidated; however, it has been suggested that it is
important only in combination with other gene variants, either within
the PSA gene itself or in other genes, such as the AR gene
(13,16,19,30). Previous studies considering the association of the
PSA G-158A polymorphism with prostate cancer have been contra-
dictory; however, many of these studies have been conducted in small
to moderately sized groups, in populations of different ethnicities, and
in studies with varying numbers of cases and controls. An initial,
relatively small study (57 cases, 156 controls) found a 3-fold in-
creased risk for advanced prostate cancer in non-Hispanic white
men with the GG genotype, and in that population, the risk of de-
veloping prostate cancer increased 5-fold when associated with short
AR alleles (16). Subsequently, smaller population-based case–control
studies by Binnie et al. (19) [100 cases, 79 benign prostatic hy-
perplasia (BPH) controls, 67 population controls] and Chiang et al.
(20) (122 cases, 84 BPH controls) have confirmed the association
between prostate cancer susceptibility and the G allele in Caucasian
(19) and Asian (20) populations, as did a larger, sibling-based case–
control study (439 cases, 479 controls) in a predominantly white
American population (17). Other moderately sized studies have re-
futed these findings, and showed an association between the A allele
Table II. Genotypic frequencies for the PSA G-158A SNP, with crude and adjusted ORs for prostate cancer risk
Genotype Genotypic frequenciesa Crude OR 95% CIs Significance P Adjusted ORb 95% CIs Significance P
Healthy controls
(n 5 223)
Men with prostate
cancer (n 5 209)
GG 0.32 0.17 Referent — — Referent — —
AG 0.48 0.53 2.03 1.25–3.28 0.001c 2.44 1.23–4.81 0.012c
AA 0.20 0.30 2.76 1.59–4.81 — 3.00 1.36–6.52 —
AA/AGd 0.68 0.83 2.25 1.42–3.54 0.001 2.61 1.37–4.96 0.004
aBoth populations were in Hardy–Weinberg equilibrium (P  0.31).
bMultivariate model adjusted for age (there was no confounding from other variables).
cTest for significance of trend.
dOn a dominant model.
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and increased risk of prostate cancer in a Portuguese population (151
case, 127 controls) (14) and an Austrian population (190 cases, 190
BPH controls) (18). However, larger studies have shown no significant
association between the G-158A SNP and risk of prostate cancer in
a Finnish population (968 cases, 923 population controls) (21) or in
a predominantly white American population (591 cases, 538 popula-
tion controls) (22) or a Japanese population (300 cases, 216 BPH
controls, 266 controls) (23).
Since G-158A allele frequencies have been shown to be signifi-
cantly different between various populations and different studies, the
importance of the distribution of the G-158A polymorphism between
different ethnic groups, and with respect to prostate cancer suscepti-
bility in these groups, remains a subject of some debate. It has been
reported that the alleles occur with approximately equal frequencies
(50% A, 50% G) in both white American and African-American
populations (15); however, other reports have shown that the G allele
is slightly more common among African-American populations
(55%), than white American populations (16). Our study revealed that
the G allele occurred less frequently (32%) in an Australian white
population than in other white populations. It has also been shown that
the GG genotype is more common in Japanese-Americans (64%),
compared with Hispanic (37%), non-Hispanic white (29%) and black
American (24%) populations (13), European white populations (30%)
(14) and this Australian white population (32%). Most interestingly,
however, the158A allele has been consistently reported to be under-
represented in Asian populations (13,16,20,23,27), which have a lower
incidence of prostate cancer, when compared with Caucasians and
African-Americans. The role of other genetic variants in modifying
the association with G-158A cannot be discounted, for example, vary-
ing numbers of CAG repeats in the AR gene between different ethnic
groups may account for discordance between different studies.
It has been proposed that the G-158A polymorphism is associated
with circulating serum levels of PSA and/or disease stage (as measured
by tumour histology or grade) (11,13,17–20). Higher serum PSA levels
have been shown to be associated with the A allele or AA genotype
(13,14) in some studies, and with the A/G or G/G genotype in others
(11,12). However, we found no association with any of the clinical
parameters measured in men with prostate cancer cases, including
serum PSA at diagnosis, TNM stage or Gleason score. This may be
a function of the relatively small numbers within each clinical sub-
group in this study.
In conclusion, we have used a number of sensitive in vitro assays to
identify a possible functional role for the G-158A polymorphism in
AREI of the PSA gene, by showing that the A allele confers greater
androgen responsiveness and shows a greater affinity for the AR than
the G allele. We have also shown an association between the PSA
AREI-G-158A polymorphism and risk of developing prostate cancer
in a well-characterized, albeit moderately sized, Australian Caucasian
population. Our results suggest that the G-158A polymorphism may
be one mechanism by which PSA expression is altered and predis-
poses to prostate cancer.
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